Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020

We review the interaction between coronavirus disease (COVID-19) and coccidioidomycosis, a respiratory infection caused by inhalation of Coccidioides fungal spores in dust. We examine risk for co-infection among construction and agricultural workers, incarcerated persons, Black and Latino populatio...

Full description

Bibliographic Details
Main Authors: Alexandra K. Heaney, Jennifer R. Head, Kelly Broen, Karen Click, John Taylor, John R. Balmes, Jon Zelner, Justin V. Remais
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2021-05-01
Series:Emerging Infectious Diseases
Subjects:
Online Access:https://wwwnc.cdc.gov/eid/article/27/5/20-4661_article
id doaj-cc2c89827c3f4dec80409157ea7d4b84
record_format Article
spelling doaj-cc2c89827c3f4dec80409157ea7d4b842021-04-23T11:13:34ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592021-05-012751266127310.3201/eid2705.204661Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020Alexandra K. HeaneyJennifer R. HeadKelly BroenKaren ClickJohn TaylorJohn R. BalmesJon ZelnerJustin V. Remais We review the interaction between coronavirus disease (COVID-19) and coccidioidomycosis, a respiratory infection caused by inhalation of Coccidioides fungal spores in dust. We examine risk for co-infection among construction and agricultural workers, incarcerated persons, Black and Latino populations, and persons living in high dust areas. We further identify common risk factors for co-infection, including older age, diabetes, immunosuppression, racial or ethnic minority status, and smoking. Because these diseases cause similar symptoms, the COVID-19 pandemic might exacerbate delays in coccidioidomycosis diagnosis, potentially interfering with prompt administration of antifungal therapies. Finally, we examine the clinical implications of co-infection, including severe COVID-19 and reactivation of latent coccidioidomycosis. Physicians should consider coccidioidomycosis as a possible diagnosis when treating patients with respiratory symptoms. Preventive measures such as wearing face masks might mitigate exposure to dust and severe acute respiratory syndrome coronavirus 2, thereby protecting against both infections. https://wwwnc.cdc.gov/eid/article/27/5/20-4661_articleCOVID-19coccidioidomycosisco-infectionsdiagnosisrisk factorsSARS-CoV-2
collection DOAJ
language English
format Article
sources DOAJ
author Alexandra K. Heaney
Jennifer R. Head
Kelly Broen
Karen Click
John Taylor
John R. Balmes
Jon Zelner
Justin V. Remais
spellingShingle Alexandra K. Heaney
Jennifer R. Head
Kelly Broen
Karen Click
John Taylor
John R. Balmes
Jon Zelner
Justin V. Remais
Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020
Emerging Infectious Diseases
COVID-19
coccidioidomycosis
co-infections
diagnosis
risk factors
SARS-CoV-2
author_facet Alexandra K. Heaney
Jennifer R. Head
Kelly Broen
Karen Click
John Taylor
John R. Balmes
Jon Zelner
Justin V. Remais
author_sort Alexandra K. Heaney
title Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020
title_short Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020
title_full Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020
title_fullStr Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020
title_full_unstemmed Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020
title_sort coccidioidomycosis and covid-19 co-infection, united states, 2020
publisher Centers for Disease Control and Prevention
series Emerging Infectious Diseases
issn 1080-6040
1080-6059
publishDate 2021-05-01
description We review the interaction between coronavirus disease (COVID-19) and coccidioidomycosis, a respiratory infection caused by inhalation of Coccidioides fungal spores in dust. We examine risk for co-infection among construction and agricultural workers, incarcerated persons, Black and Latino populations, and persons living in high dust areas. We further identify common risk factors for co-infection, including older age, diabetes, immunosuppression, racial or ethnic minority status, and smoking. Because these diseases cause similar symptoms, the COVID-19 pandemic might exacerbate delays in coccidioidomycosis diagnosis, potentially interfering with prompt administration of antifungal therapies. Finally, we examine the clinical implications of co-infection, including severe COVID-19 and reactivation of latent coccidioidomycosis. Physicians should consider coccidioidomycosis as a possible diagnosis when treating patients with respiratory symptoms. Preventive measures such as wearing face masks might mitigate exposure to dust and severe acute respiratory syndrome coronavirus 2, thereby protecting against both infections.
topic COVID-19
coccidioidomycosis
co-infections
diagnosis
risk factors
SARS-CoV-2
url https://wwwnc.cdc.gov/eid/article/27/5/20-4661_article
work_keys_str_mv AT alexandrakheaney coccidioidomycosisandcovid19coinfectionunitedstates2020
AT jenniferrhead coccidioidomycosisandcovid19coinfectionunitedstates2020
AT kellybroen coccidioidomycosisandcovid19coinfectionunitedstates2020
AT karenclick coccidioidomycosisandcovid19coinfectionunitedstates2020
AT johntaylor coccidioidomycosisandcovid19coinfectionunitedstates2020
AT johnrbalmes coccidioidomycosisandcovid19coinfectionunitedstates2020
AT jonzelner coccidioidomycosisandcovid19coinfectionunitedstates2020
AT justinvremais coccidioidomycosisandcovid19coinfectionunitedstates2020
_version_ 1721512816797548544